Ensuring Chain of Custody in Clinical Trial Logistics

Introduction: Why Chain of Custody Matters

Chain of custody (CoC) refers to the documented and unbroken trail showing the movement and handling of investigational medicinal products (IMPs) from manufacturer to depot, site, and ultimately the patient. For US sponsors, the FDA requires that every transfer of custody is recorded, ensuring accountability, product integrity, and patient safety. Inadequate custody documentation can result in Form 483s, warning letters, and, in some cases, trial suspension.

Data from the EU Clinical Trials Register highlights that nearly 18% of logistics-related findings during inspections were due to incomplete custody records. With increasingly global and decentralized trials, ensuring an unbroken chain of custody has become both more difficult and more important.

Regulatory Expectations for Chain of Custody

Regulatory frameworks require full accountability across custody transfers:

• FDA 21 CFR Part 312.57: Sponsors must maintain detailed shipment, transfer, and disposition records for IMPs.
• FDA 21 CFR Part 211: Requires control systems to ensure IMPs are stored and distributed in accordance with labeled conditions.
• ICH E6(R3): Requires investigators and sponsors to ensure accountability of IMPs at every stage, including custody transfers.
• EMA GDP: Mandates documentation of custody handovers, courier compliance, and storage conditions.

WHO further emphasizes that chain of custody safeguards protect against counterfeit or diverted products in vulnerable supply chains. Regulators expect documented evidence that no custody gap exists throughout the trial lifecycle.

Audit Findings in Custody Oversight

FDA and sponsor audits frequently cite deficiencies in custody management:

Example: In a Phase III oncology trial, FDA inspectors identified missing handover signatures in courier logs. The sponsor received a critical observation for inadequate chain-of-custody documentation.

Root Causes of Custody Oversight Failures

Root cause analysis often identifies:

• Absence of standardized custody SOPs across depots, couriers, and sites.
• Over-reliance on paper logs prone to transcription and loss.
• Insufficient sponsor oversight of courier and depot custody practices.
• Untrained staff at sites failing to maintain custody documentation.

Case Example: In a vaccine trial, custody gaps were identified between depot release and site receipt. Investigation showed couriers were subcontracting deliveries without sponsor authorization, resulting in missing custody records.

Corrective and Preventive Actions (CAPA) for Chain of Custody

To meet FDA and EMA expectations, sponsors must embed CAPA into custody oversight:

1. Immediate Correction: Reconcile custody records, quarantine affected IMPs, and retrain staff involved.
2. Root Cause Analysis: Identify systemic issues such as missing SOPs, inadequate vendor oversight, or poor training.
3. Corrective Actions: Revise SOPs, implement electronic custody systems, and qualify vendors.
4. Preventive Actions: Conduct annual audits, enforce contractual clauses on custody, and integrate custody logs into eTMF systems.

Example: A US sponsor implemented electronic custody tracking linked with GPS-enabled courier systems. This reduced missing custody logs by 95% and improved FDA inspection outcomes.

Best Practices in Custody Oversight

To ensure compliance, US sponsors should adopt the following practices:

• Develop SOPs covering all custody transfers, including depots, couriers, and sites.
• Use electronic custody systems with audit trails and automated reconciliation.
• Qualify couriers and depots through GDP-focused audits.
• Train site and depot staff on custody documentation requirements.
• Archive custody records in the Trial Master File (TMF).

KPIs for custody oversight:

Case Studies of Custody Deficiencies

Case 1: FDA cited a sponsor in a cardiovascular trial for custody gaps between depot and site records.
Case 2: EMA inspection identified missing courier custody logs in a rare disease trial.
Case 3: WHO audit observed lack of custody SOPs in a multi-country vaccine program, raising risks of diversion.

Conclusion: Treating Custody as a Compliance Imperative

Chain of custody is not a clerical exercise—it is a compliance-critical requirement. For US sponsors, FDA expects full custody documentation, reconciliation, and vendor oversight. By embedding CAPA, digitizing custody records, and qualifying vendors, sponsors can ensure inspection readiness and protect patient safety.

Sponsors that treat custody oversight as a strategic compliance function not only reduce audit findings but also strengthen trust in trial data and regulatory submissions.